Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on September 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Results cover three months and transitional fiscal year ended June 30, 2026.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Results cover three months and transitional fiscal year ended June 30, 2026
- Press release issued September 21, 2026, with detailed financial results in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Jemperli sales reached $644M for six months, up 34% year over year, strengthening Anaptys’ royalty-driven cash flow outlook
- Anaptys expects annualized Jemperli royalties above $390M by 2029 at GSK peak sales guidance above $2.7B
- Cash and investments fell to $164.1M from $211.6M, while $256.5M remained under future-royalty sale obligations
- $181.5M tax benefit drove $176.4M continuing-operations net income, making reported earnings heavily tax-related
- GSK litigation judgment expected Q4 2026 or Q1 2027, with Anaptys seeking reversion of Jemperli rights as a remedy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.